Mining FDA Databases for Cybersecurity Precedent

Cybersecurity precedent research is not a summary read. Done well, it is a structured pass through five FDA data sources that together tell you what the agency has actually accepted, redacted, or challenged in your product code. The February 3, 2026 final premarket cybersecurity guidance is the rulebook, but cleared submissions are the answer key.

This guide is the workflow we run internally before we produce a Section 524B artifact for any new client device. It assumes you have already read the companion post on navigating the 510(k), De Novo, and PMA databases and want the operational sequence.

Key Takeaways

• Precedent research is a five-source workflow (Product Classification, 510(k), De Novo, PMA, MAUDE, FOIA), not a single database search.
• Product code and regulation number scope the search; device name is unreliable.
• De Novo Decision Summaries and PMA SSEDs carry the deepest FDA-authored cybersecurity reasoning in the public record.
• FOIA exemption (b)(4) redactions still expose the structure of the submission, which is often what matters most.
• MAUDE closes the postmarket loop by showing cybersecurity-adjacent failure modes for cleared devices in the same code.
• The output of precedent research should be a written baseline: SBOM format, threat-model methodology, pen-test scope, and postmarket plan structure the FDA is currently accepting for your device category.

Table of Contents

• Why Precedent Research Matters Under Section 524B
• Step 1: Anchor the Search in the Product Classification Database
• Step 2: Read Post-524B 510(k) Clearances in Your Product Code
• Step 3: Read the De Novo Grant That Created Your Product Code
• Step 4: Read PMA SSEDs and Supplements for Change-Control Precedent
• Step 5: Cross-Reference MAUDE and the FOIA Reading Room
• How to Turn Precedent Findings Into Submission-Ready Evidence
• How Blue Goat approaches this
• FAQ

Why Precedent Research Matters Under Section 524B

Section 524B of the FD&C Act made cybersecurity a gating requirement for every "cyber device," and the FDA's February 2026 final premarket cybersecurity guidance defines the artifacts reviewers expect: SBOM, threat model, security risk assessment, security architecture views, penetration test, labeling, and postmarket vulnerability management plan. The guidance is uniform, but reviewer application is product-code specific.

Precedent research tells you where the current bar sits for your code. Reviewers for infusion pumps, continuous glucose monitors, and radiation therapy planning software have different threat surfaces in mind even when they cite the same guidance sections. Reading three to five cleared post-524B submissions in your product code before you file is the fastest way to calibrate depth so the first-cycle review does not turn into an AI-letter exchange.

Standards including AAMI TIR57, ANSI/AAMI SW96, and IEC 81001-5-1 are named in the guidance, but the way cleared summaries reference them (or do not) shows how strictly a specific review team is currently reading them.

Step 1: Anchor the Search in the Product Classification Database

Start at the FDA Product Classification Database. Search by device name or intended use to identify the three-letter product code and the 21 CFR regulation number for the device family. Note:

• The device class (I, II, or III), which determines pathway and cybersecurity scrutiny
• Any special controls listed against the regulation number
• The submission type the code typically clears under (510(k), De Novo, PMA)
• Whether the code was created by a De Novo grant, which the classification entry usually notes

Everything downstream is keyed to this product code. Device-name searches miss synonyms and rebrands.

Step 2: Read Post-524B 510(k) Clearances in Your Product Code

Open the 510(k) Premarket Notification Database, filter by product code, sort by decision date descending, and read the three to five most recent clearances issued after Section 524B took effect. For each Summary Statement:

• Note whether the sponsor references the February 2026 final guidance, AAMI SW96, IEC 81001-5-1, or SPDX/CycloneDX SBOM format by name
• Look for phrases like "cybersecurity risk assessment," "threat model," "penetration testing," and "coordinated vulnerability disclosure"
• Flag redactions marked (b)(4) and note the section headings around them, structure is often more informative than the redacted content
• Record the predicate K-number, so you can walk the predicate chain back to the original clearance

Step 3: Read the De Novo Grant That Created Your Product Code

If Step 1 showed your product code was created by a De Novo grant, pull the grant from the De Novo Database and read the full Decision Summary. The Decision Summary is written by the FDA and is the single most valuable cybersecurity precedent document in the public record because it names:

• The specific device risks the agency identified
• The special controls the agency imposed (which become mandatory for every follow-on 510(k))
• The cybersecurity, software, and interoperability evidence the sponsor provided
• The FDA's reasoning for accepting or rejecting specific mitigations

De Novo cybersecurity special controls are precedent that outlives the grant. If your product code has them, your submission has to address them by name.

Step 4: Read PMA SSEDs and Supplements for Change-Control Precedent

If the device category clears under PMA, pull the most recent approvals in your product code from the PMA Database and read the Summary of Safety and Effectiveness Data (SSED) for each. Then walk the supplement chain (S001, S002, and so on) to see how the FDA handled post-approval cybersecurity changes.

See also: FDA 510(k), De Novo, and PMA Databases: Cybersecurity Guide, Letter to File vs New 510(k), and Special vs Traditional 510(k).

Supplements are especially valuable if you plan to file a Predetermined Change Control Plan. They show which categories of cybersecurity change the FDA has previously accepted through PMA supplements, which is directly informative for scoping a PCCP under the December 2024 final PCCP guidance. See our PCCP and cybersecurity guides collection for how to convert that precedent into a submission-ready PCCP.

Step 5: Cross-Reference MAUDE and the FOIA Reading Room

Premarket databases end at clearance. To see what happened after, use:

• MAUDE, for adverse event reports in your product code. Filter by device problem codes related to software, connectivity, and unauthorized access to find cybersecurity-adjacent postmarket signals.
• FDA FOIA reading room, which occasionally releases redacted review memos, warning letters, and 483 observations with cybersecurity content.
• 510(k) Third Party Review lists, to see which product codes have accelerated review paths.

MAUDE will not name a "cybersecurity incident" as such, but device-problem code patterns (software issues, communication failures, unexpected behavior) in your product code often correlate to the postmarket cybersecurity risks the FDA now expects your submission to address.

How to Turn Precedent Findings Into Submission-Ready Evidence

Precedent research is only useful if it changes what you file. The deliverable should be a short written baseline that answers, for your product code:

• What SBOM format has been accepted in recent post-524B clearances (SPDX, CycloneDX, both)?
• What threat-model methodology appears (STRIDE, PASTA, TIR57-aligned custom)?
• What penetration-test scope is treated as complete (RF, BLE, firmware, cloud APIs, mobile apps)?
• Which standards are consistently cited by name (AAMI SW96, IEC 81001-5-1, ISO 14971)?
• What postmarket cybersecurity plan structure appears in cleared submissions?

That baseline becomes the calibration point for your artifacts. If your SBOM, threat model, or pen-test scope is materially thinner than the precedent baseline, you are filing below the current bar. Cross-check against the specific patterns in our 510(k) cybersecurity deficiencies that trigger FDA holds analysis and our FDA cybersecurity deficiency letter examples library before you submit. For AI/ML or firmware-updatable devices, feed the change-authority precedent you find into a Predetermined Change Control Plan so post-clearance updates stay inside the cleared envelope.

Want the precedent baseline built for your product code before you file? Schedule a scoping call and we will pull the post-524B clearances in your code and hand you the calibrated baseline.

How Blue Goat approaches this

Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. Precedent research is the first hour of every new engagement: we pull every post-Section-524B clearance in the client's product code, reconstruct the cybersecurity evidence pattern the FDA has been accepting, and set that as the floor for the artifacts we produce.

The result is a submission calibrated to how reviewers in that product code are currently reading the February 2026 guidance, not to a generic template. See our FDA premarket cybersecurity services for the full scope. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

How do I mine FDA databases for medical device cybersecurity precedent?

Start at the Product Classification Database to lock in the product code, then read post-Section-524B 510(k) Summary Statements, the De Novo Decision Summary that created the code, and any recent PMA SSEDs and supplements in the same code. Close with MAUDE and the FOIA reading room for postmarket signals. Product code, not device name, is the correct search key throughout.

What FDA cybersecurity content is public and what is redacted?

Structural content, submission section headings, artifact types, standards references, and predicate chains, is almost always public. Specific technical detail (encryption implementation, exploitation findings, proprietary threat-model content) is typically redacted under FOIA exemption (b)(4). The structure that remains is usually enough to calibrate documentation depth.

Are pre-Section-524B 510(k) clearances useful precedent?

For predicate identification, yes. For cybersecurity documentation depth, no. Pre-524B clearances predate the current mandatory cybersecurity content requirements and do not reflect how the February 2026 guidance is being applied today.

How do De Novo cybersecurity special controls apply to follow-on 510(k) submissions?

When a De Novo grant creates a product code with cybersecurity special controls, every subsequent 510(k) in that code must demonstrate substantial equivalence to those controls. The Decision Summary is precedent that carries forward regardless of how much time has passed since the original grant.

Can MAUDE show cybersecurity incidents in a product code?

MAUDE does not tag reports as "cybersecurity," but device-problem code patterns tied to software, communications, and unexpected behavior in your product code often correlate to the postmarket cybersecurity risks the FDA now expects your submission to anticipate. Treat MAUDE as a signal source, not a definitive incident record.

Related: How to Navigate the FDA 510(k), De Novo, and PMA Databases for Cybersecurity · FDA Pathway Cybersecurity Differences · FDA Cybersecurity Deficiency Letter Examples · FDA PCCP Change-Control Plans

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.